PacBio Onso™ Short Read Sequencing Instrument Joins 10x Genomics Compatible Partner Program
PacBio (Nasdaq: PACB) has announced the inclusion of its Onso short-read sequencing platform in the 10x Genomics Compatible Partner Program. This program recognizes instruments and workflows compatible with 10x Genomics' products and applications, expanding sequencing solutions for researchers worldwide.
The Onso platform, known for its exceptional accuracy in short-read sequencing, aligns well with 10x Genomics' tools for single-cell and spatial biology applications. It joins PacBio's MAS-seq long read RNA sequencing solution in the program, as part of PacBio's effort to provide integrated workflows for genomics and transcriptomics research.
Key benefits of this collaboration include:
- Streamlined workflows combining PacBio's Onso platform with 10x Genomics' technologies
- Compatibility with 10x Genomics' Single Cell 3' v3.1 assay
- Enhanced data quality and efficiency in research
- Unmatched sequencing accuracy from PacBio's Onso platform
PacBio (Nasdaq: PACB) ha annunciato l'inclusione della sua piattaforma di sequenziamento Onso short-read nel Programma Partner Compatibile con 10x Genomics. Questo programma riconosce strumenti e flussi di lavoro compatibili con i prodotti e le applicazioni di 10x Genomics, ampliando le soluzioni di sequenziamento per i ricercatori in tutto il mondo.
La piattaforma Onso, nota per la sua eccezionale accuratezza nel sequenziamento short-read, si integra bene con gli strumenti di 10x Genomics per applicazioni di biologia cellulare singola e spaziale. Si unisce alla soluzione di sequenziamento RNA long read MAS-seq di PacBio nel programma, come parte dell'impegno di PacBio per fornire flussi di lavoro integrati per la ricerca genomica e trascrittomica.
I principali vantaggi di questa collaborazione includono:
- Flussi di lavoro semplificati che combinano la piattaforma Onso di PacBio con le tecnologie di 10x Genomics
- Compatibilità con l'analisi Single Cell 3' v3.1 di 10x Genomics
- Qualità dei dati migliorata e maggiore efficienza nella ricerca
- Accuratezza di sequenziamento senza pari dalla piattaforma Onso di PacBio
PacBio (Nasdaq: PACB) ha anunciado la inclusión de su plataforma de secuenciación Onso short-read en el Programa de Socios Compatibles con 10x Genomics. Este programa reconoce instrumentos y flujos de trabajo compatibles con los productos y aplicaciones de 10x Genomics, ampliando las soluciones de secuenciación para los investigadores de todo el mundo.
La plataforma Onso, conocida por su excepcional precisión en el secuenciamiento short-read, se alinea bien con las herramientas de 10x Genomics para aplicaciones de biología de células individuales y espacial. Se une a la solución de secuenciación de RNA long read MAS-seq de PacBio en el programa, como parte del esfuerzo de PacBio por proporcionar flujos de trabajo integrados para la investigación genómica y transcriptómica.
Los beneficios clave de esta colaboración incluyen:
- Flujos de trabajo optimizados que combinan la plataforma Onso de PacBio con las tecnologías de 10x Genomics
- Compatibilidad con el ensayo Single Cell 3' v3.1 de 10x Genomics
- Calidad de datos mejorada y eficiencia en la investigación
- Precisión de secuenciamiento inigualable de la plataforma Onso de PacBio
PacBio (Nasdaq: PACB)는 Onso 단기 읽기 시퀀싱 플랫폼의 10x Genomics 호환 파트너 프로그램 포함을 발표했습니다. 이 프로그램은 10x Genomics의 제품 및 응용 프로그램과 호환되는 기기 및 작업 흐름을 인정하여 전 세계 연구자들을 위한 시퀀싱 솔루션을 확장합니다.
단기 읽기 시퀀싱에서 뛰어난 정확성으로 알려진 Onso 플랫폼은 10x Genomics의 단일 세포 및 공간 생물학 응용 프로그램 도구와 잘 어울립니다. 이는 10x Genomics의 MAS-seq 장기 읽기 RNA 시퀀싱 솔루션과 함께 PacBio 프로그램에 참여하여, 유전체학 및 전사체 연구를 위한 통합 작업 흐름을 제공하려는 PacBio의 노력의 일환입니다.
이 협업의 주요 이점은 다음과 같습니다:
- PacBio의 Onso 플랫폼과 10x Genomics의 기술을 결합한 간소화된 작업 흐름
- 10x Genomics의 Single Cell 3' v3.1 분석과의 호환성
- 연구에서 향상된 데이터 품질 및 효율성
- PacBio의 Onso 플랫폼에서 제공하는 비할 데 없는 시퀀싱 정확성
PacBio (Nasdaq: PACB) a annoncé l'inclusion de sa plateforme de séquençage Onso à lecture courte dans le Programme Partenaire Compatible 10x Genomics. Ce programme reconnaît les instruments et les flux de travaux compatibles avec les produits et applications de 10x Genomics, élargissant ainsi les solutions de séquençage pour les chercheurs du monde entier.
La plateforme Onso, reconnue pour son exceptionnelle précision en séquençage à lecture courte, s'aligne bien avec les outils de 10x Genomics pour les applications en biologie des cellules uniques et en biologie spatiale. Elle rejoint la solution de séquençage d'ARN à longues lectures MAS-seq de PacBio dans le programme, dans le cadre de l'engagement de PacBio à fournir des flux de travail intégrés pour la recherche en génomique et en transcriptomique.
Les principaux avantages de cette collaboration incluent:
- Des flux de travail rationalisés combinant la plateforme Onso de PacBio avec les technologies de 10x Genomics
- Compatibilité avec le test Single Cell 3' v3.1 de 10x Genomics
- Qualité des données améliorée et efficacité de la recherche
- Précision de séquençage inégalée de la plateforme Onso de PacBio
PacBio (Nasdaq: PACB) hat die Einbeziehung seiner Onso Short-Read-Sequenzierungsplattform in das 10x Genomics Kompatible Partnerprogramm bekannt gegeben. Dieses Programm erkennt Instrumente und Workflows an, die mit den Produkten und Anwendungen von 10x Genomics kompatibel sind, und erweitert die Sequenzierungslösungen für Forscher weltweit.
Die Onso-Plattform, die für ihre außergewöhnliche Genauigkeit im Short-Read-Sequencing bekannt ist, passt gut zu den Werkzeugen von 10x Genomics für Einzelzell- und räumliche Biologieanwendungen. Sie reiht sich in die MAS-seq Long-Read-RNA-Sequenzierungslösung von PacBio im Programm ein, was Teil des Engagements von PacBio ist, integrierte Workflows für die Genomik- und Transkriptomforschung bereitzustellen.
Die Hauptvorteile dieser Zusammenarbeit umfassen:
- Vereinfachte Workflows, die die Onso-Plattform von PacBio mit den Technologien von 10x Genomics kombinieren
- Kompatibilität mit dem Single Cell 3' v3.1 Assay von 10x Genomics
- Verbesserte Datenqualität und Effizienz in der Forschung
- Unübertroffene Sequenzierungsgenauigkeit der Onso-Plattform von PacBio
- Inclusion of Onso short-read sequencing platform in 10x Genomics Compatible Partner Program
- Expansion of partnership with 10x Genomics, a leader in single-cell and spatial biology solutions
- Compatibility with 10x Genomics' Single Cell 3' v3.1 assay
- Potential for improved data quality and efficiency in genomics research
- None.
Insights
The inclusion of PacBio's Onso short-read sequencing platform in the 10x Genomics Compatible Partner Program is a significant development in the genomics industry. This collaboration enhances the interoperability between two leading technologies, potentially accelerating research in single-cell and spatial biology.
The partnership addresses a important need in the scientific community for integrated workflows that combine high-accuracy sequencing with advanced single-cell analysis tools. By streamlining these processes, researchers can expect improved data quality and efficiency in their experiments.
Particularly noteworthy is the compatibility with 10x Genomics' Single Cell 3' v3.1 assay, which could lead to more comprehensive insights into cellular heterogeneity and function. The emphasis on Onso's superior accuracy aligns well with the precision required in single-cell genomics, potentially enabling discoveries that were previously challenging to achieve.
This partnership has positive implications for PacBio's market position. By aligning with 10x Genomics, a recognized leader in single-cell and spatial genomics, PacBio gains access to a broader customer base and enhances its competitive edge in the short-read sequencing market.
The collaboration could drive increased adoption of PacBio's Onso platform, potentially leading to higher instrument placements and consumable sales. It also positions PacBio as a more comprehensive solution provider, offering both long-read (MAS-seq) and short-read (Onso) technologies compatible with 10x Genomics' systems.
For investors, this move signals PacBio's strategic focus on expanding its market reach and diversifying its product offerings. The partnership may lead to revenue growth opportunities and strengthen PacBio's competitive position against other sequencing technology providers.
MENLO PARK, Calif., Oct. 22, 2024 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading developer of high-quality, highly accurate genomic sequencing solutions, today announced the inclusion of the Onso short-read sequencing platform in the 10x Genomics Compatible Partner Program. The 10x Genomics Compatible Partner Program recognizes instruments and workflows compatible with 10x Genomics’ products and applications, thereby broadening the range of sequencing solutions available to researchers worldwide.
The Onso platform, designed to provide exceptional accuracy and performance in short-read sequencing, is well-aligned with 10x Genomics’ suite of tools for single-cell and spatial biology applications. The Onso platform joins PacBio’s MAS-seq long read RNA sequencing solution in the 10x Genomics Compatible Partner Program, as part of PacBio’s effort to empower scientists with integrated workflows that enhance insights into genomics and transcriptomics, addressing key challenges in scientific research and advancing discovery in health and disease.
"We are excited to expand our partnership with 10x Genomics, an established leader in single-cell and spatial biology solutions," said David Miller, VP of Global Marketing at PacBio. "The integration of our Onso short read sequencing instrument into their partner program signifies a major step forward for researchers looking for high-performance sequencing with superior accuracy. This collaboration will help expand the possibilities for discovery in complex biological systems and enhance our ability to support cutting-edge research in genomics."
Benefits of the Collaboration:
- Streamlined Workflows: Researchers can now access seamless end-to-end solutions by combining PacBio's Onso platform with 10x Genomics' technologies, allowing for improved data quality and efficiency.
- Enhanced Applications: The Onso platform is compatible with 10x Genomics’ Single Cell 3’ v3.1 assay.
- Industry-Leading Accuracy: PacBio's Onso platform delivers unmatched sequencing accuracy, further enhancing the precision of 10x Genomics' cutting-edge research tools.
"We are thrilled to welcome the PacBio Onso platform into the 10x Genomics Compatible Partner Program," said Rena Bradham, VP and Global Head of Marketing at 10x Genomics. "PacBio’s innovative approach to short read sequencing, paired with our leading single-cell technologies, provides an integrated solution that will enable researchers to push the boundaries of genomic science."
About Pacific Biosciences
PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
About 10x Genomics
10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter).
Forward-Looking Statements:
This press release may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to the uses, coverage, advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies, including in connection with 10x’s anticipate use of Onso; and other future events. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties and could cause actual outcomes and results to differ materially from currently anticipated results, including, challenges inherent in sequencing a large number of genomes, and the difficulty of generating discoveries across various areas of research; potential product performance and quality issues; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights; and other risks associated with international operations. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption "Risk Factors." These forward-looking statements are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.
Contacts (PacBio)
Investors:
Todd Friedman
ir@pacificbiosciences.com
Media:
pr@pacficbiosciences.com
Contacts (10x)
Media:
Kristen Cardillo
kristen.cardillo@10xgenomics.com
FAQ
What is the significance of PacBio's Onso platform joining the 10x Genomics Compatible Partner Program?
How does the Onso platform (PACB) complement 10x Genomics' technologies?
What specific 10x Genomics assay is compatible with PacBio's Onso platform?
How does the collaboration between PacBio (PACB) and 10x Genomics benefit researchers?
